Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. Issue 4 (6th August 2012)

• Record Type: Journal Article
• Authors: Murakami, Yoshiaki; Uemura, Kenichiro; Sudo, Takeshi; Hashimoto, Yasushi; Nakashima, Akira; Kondo, Naru; Nakagawa, Naoya; Sueda, Taijiro
• Is Part Of: Journal of surgical oncology. Volume 107:Issue 4(2013:Mar. 15)
• Page Start: 414
• Page End: 421
• Publication Date: 2012-08-06
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23229
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>Background and Objectives</title> <p>The aim of this study was to evaluate the efficacy of portal or superior mesenteric vein (PV/SMV) resection for patients with pancreatic carcinoma who underwent pancreatoduodenectomy.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>Methods</title> <p>Medical records of 125 patients with pancreatic head carcinoma who underwent pancreatoduodenectomy were reviewed retrospectively. Sixty‐one patients underwent PV/SMV resection and 64 patients did not. Clinicopathological factors were compared between the two groups and the prognostic impact of PV/SMV resection was evaluated using univariate and multivariate survival analysis.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>Results</title> <p>The frequency of mortality and morbidity did not differ between the two groups. Univariate analysis revealed that a significant difference in overall survival was found between patients who did and did not undergo PV/SMV resection (<italic>P</italic> = 0.046) as well as between patients with and without pathological PV/SMV invasion (<italic>P</italic> = 0.012). However, PV/SMV resection and pathological PV/SMV invasion were not independent prognostic factors by multivariate survival analysis. Among patients with PV/SMV resection, the use of adjuvant chemotherapy was the only independent prognostic factor of overall survival (<italic>P</italic> = 0.003).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>Conclusions</title> <p>Resection of the PV/SMV with adjuvant chemotherapy may provide an acceptable survival benefit to patients with pancreatic head carcinoma, which involves the PV/SMV without additional mortality and morbidity. J. Surg. Oncol. 2013;107:414–421. © 2012 Wiley Periodicals, Inc.</p> </sec> </abstract>